Navigation Links
Cardium to Present at Upcoming Investor Conferences
Date:1/4/2012

SAN DIEGO, Jan. 4, 2012 /PRNewswire/ -- Cardium Therapeutics (NYSE Amex: CXM) today announced that it is scheduled to present at the Biotech Showcase 2012 and the 5th Annual OneMedForum Conference in San Francisco.

(Logo: http://photos.prnewswire.com/prnh/20051018/CARDIUMLOGO)

The 2012 Biotech Showcase is being held at the Parc 55 Wyndham in San Francisco and Cardium is scheduled to present on Monday, January 9, 2012 at 4:00 p.m. Pacific.

The 5th Annual OneMedForum Conference is taking place at the Sir Francis Drake Hotel, San Francisco and the Company's presentation is scheduled for Tuesday, January 10, 2012 at 11:00 a.m. Pacific.  OneMedForum Conference provides a live, video web cast that can be found at http://www.onemedplace.com/.

An updated investor presentation is now available on Cardium's website at http://phx.corporate-ir.net/phoenix.zhtml?c=77949&p=irol-presentations.

About Cardium
Cardium is focused on the acquisition and strategic development of new and innovative bio-medical product opportunities and businesses with the potential to address significant unmet medical needs that have definable pathways to commercialization, partnering and other economic monetizations.  Cardium's current medical opportunities portfolio, which is focused on health sciences and regenerative medicine, includes the Tissue Repair Company, Cardium Biologics, and the Company's in-house MedPodium Health Sciences healthy lifestyle product platform.  The Company's lead commercial product Excellagen™ topical gel for wound care management, has recently received FDA clearance for marketing and sale in the United States.  Cardium's lead clinical development product candidate Generx®is a DNA-based angiogenic biologic intended for the treatment of patients with myocardial ischemia due to coronary artery disease.  In addition, consistent with its capital-efficient business model, Cardium continues to actively evaluate new technologies and business opportunities.  In July 2009, Cardium completed the sale of its InnerCool Therapies medical device business to Royal Philips Electronics, the first asset monetization from the Company's biomedical investment portfolio. News from Cardium is located at www.cardiumthx.com.

Copyright 2012 Cardium Therapeutics, Inc.  All rights reserved.
For Terms of Use Privacy Policy, please visit www.cardiumthx.com.
Cardium Therapeutics®, Generx®, Cardionovo™, Tissue Repair™, Gene Activated Matrix™, GAM™, Excellagen™, Excellarate™, Osteorate™, MedPodium™, Appexium™, Linee™, Alena™, Cerex™, and Nutra-Apps™, Neo-Energy™, and Neo-Carb Bloc™ are trademarks of Cardium Therapeutics, Inc. or Tissue Repair Company.
(Other trademarks belong to their respective owners)

 


'/>"/>
SOURCE Cardium Therapeutics
Copyright©2010 PR Newswire.
All rights reserved

Related biology technology :

1. Cardiums Exchange Listing Compliance Plan Accepted by NYSE Amex
2. Cardium Reports Excellagen Matrix Clinical Study Results Accepted for Publication by Peer-Reviewed Journal, and Updates Product Plans
3. Cardium Reports on Third Quarter 2010 Financial Results and Recent Developments
4. Cardium to Present at the LifeTech Capital Miami Medical Investors Conference
5. Cardium Gains Exclusive Access to Novel Polymer-Based Nitric Oxide Technology for Expansion of Wound Healing Product Portfolio
6. Cardium to Present at 10th Annual Biotech in Europe Investor Forum
7. Cardium Regains Listing Compliance With NYSE Amex
8. Cardium to Present at MDB Capital Groups 2010 Bright Lights Conference
9. Cardiums Exchange Listing Compliance Plan Accepted by NYSE AMEX
10. Cardium Reports on Third Quarter 2009 Financial Results and Recent Developments
11. Cardium Announces Plans to File FDA 510(k) Application for U.S. Marketing Clearance of ExcellagenXL(TM) Gel for Diabetic, Pressure and Venous Ulcers and Other Topical Wounds
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:10/11/2017)... and LAGUNA HILLS, Calif. , Oct. ... Cancer Research, London (ICR) and University ... SKY92, SkylineDx,s prognostic tool to risk-stratify patients with multiple myeloma ... MUK nine . The University of Leeds ... partly funded by Myeloma UK, and ICR will perform the ...
(Date:10/10/2017)... ... 2017 , ... San Diego-based team building and cooking events company, Lajollacooks4u, has ... The bold new look is part of a transformation to increase awareness, appeal to ... period. , It will also expand its service offering from its signature gourmet cooking ...
(Date:10/10/2017)... 10, 2017 International research firm Parks Associates announced ... at the TMA 2017 Annual Meeting , October 11 in ... residential home security market and how smart safety and security products impact ... Parks Associates: Smart Home ... "The residential security market has ...
(Date:10/9/2017)... DIEGO , Oct. 9, 2017  BioTech ... biological mechanism by which its ProCell stem cell ... critical limb ischemia.  The Company, demonstrated that treatment ... amount of limbs saved as compared to standard ... the molecule HGF resulted in reduction of therapeutic ...
Breaking Biology Technology:
(Date:3/28/2017)... , March 28, 2017 The ... Hardware (Camera, Monitors, Servers, Storage Devices), Software (Video Analytics, ... Region - Global Forecast to 2022", published by MarketsandMarkets, ... 2016 and is projected to reach USD 75.64 Billion ... and 2022. The base year considered for the study ...
(Date:3/24/2017)... 24, 2017 The Controller General of Immigration from ... Abdulla Algeen have received the prestigious international IAIR Award for the ... Continue Reading ... ... Controller Abdulla Algeen (small picture on the right) have received the IAIR ...
(Date:3/23/2017)... The report "Gesture Recognition and Touchless Sensing Market by Technology (Touch-based ... to 2022", published by MarketsandMarkets, the market is expected to be worth USD ... 2022. Continue Reading ... ... ...
Breaking Biology News(10 mins):